NASDAQ:RCM - R1 RCM Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.81 +0.02 (+0.23 %)
(As of 07/19/2018 04:06 AM ET)
Previous Close$8.79
Today's Range$8.62 - $8.83
52-Week Range$3.05 - $9.40
Volume483,800 shs
Average Volume519,188 shs
Market Capitalization$955.11 million
P/E Ratio-19.82
Dividend YieldN/A
R1 RCM logoR1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves single or multi-hospital healthcare systems, and their respective affiliated ambulatory clinics and physician practice groups. The company was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.

Receive RCM News and Ratings via Email

Sign-up to receive the latest news and ratings for RCM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Management services
Sub-IndustryHealth Care Services


Debt-to-Equity RatioN/A
Current Ratio2.23
Quick Ratio2.23


Trailing P/E Ratio-19.82
Forward P/E Ratio-51.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$449.80 million
Price / Sales2.15
Cash FlowN/A
Price / CashN/A
Book Value$0.32 per share
Price / Book27.53


EPS (Most Recent Fiscal Year)($0.44)
Net Income$-58,800,000.00
Net Margins-14.47%
Return on Equity-45.77%
Return on Assets-7.12%


Outstanding Shares109,660,000
Market Cap$955.11

The Truth About Cryptocurrencies

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

How were R1 RCM's earnings last quarter?

R1 RCM (NASDAQ:RCM) released its quarterly earnings results on Wednesday, May, 9th. The financial services provider reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by $0.11. The financial services provider had revenue of $147.30 million for the quarter, compared to the consensus estimate of $146 million. R1 RCM had a negative net margin of 14.47% and a negative return on equity of 45.77%. View R1 RCM's Earnings History.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for R1 RCM.

What price target have analysts set for RCM?

3 analysts have issued 1 year target prices for R1 RCM's stock. Their predictions range from $9.00 to $10.00. On average, they anticipate R1 RCM's share price to reach $9.3333 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Ratings for R1 RCM.

What is the consensus analysts' recommendation for R1 RCM?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about R1 RCM stock?

Here are some recent quotes from research analysts about R1 RCM stock:
  • 1. According to Zacks Investment Research, "R1 RCM Inc. offers financial services for the health care industries. The Company provides revenue cycle management and physician advisory services, as well as transforms and manages the commercial infrastructure of health care organizations. R1 RCM Inc., formerly known as Accretive Health, Inc., is headquartered in Chicago, Illinois. " (7/18/2018)
  • 2. Cantor Fitzgerald analysts commented, "The revenue cycle management market represents a significant opportunity. Revenue cycle management remains an underdeveloped and fragmented market. There are many different solutions available, including consulting arrangements, point-solution technologies, and transactional outsourcing. Many providers use fragmented solutions. As a result, healthcare organizations are increasingly dissatisfied with currently available options and see a strong commercial partner to help improve performance and increase ROI. We estimate the market opportunity will increase to almost $70 billion by 2020. In addition, increasing consolidation among providers should lead to additional outsourcing. We expect revenue cycle outsourcing to grow to $7.7 billion by 2020 from $3.8 billion in 2015. We estimate the ambulatory market opportunity is approximately $30-40 billion. As hospital systems acquire physician offices, we expect the ambulatory market opportunity to expand." (3/13/2018)

Who are some of R1 RCM's key competitors?

Who are R1 RCM's key executives?

R1 RCM's management team includes the folowing people:
  • Mr. Joseph Gerard Flanagan, Pres, CEO & Director (Age 47)
  • Mr. Christopher Simon Ricaurte, CFO & Treasurer (Age 58)
  • Mr. Thomas A. Lesica, Exec. VP of Bus. Transformation (Age 58)
  • Mr. Gary S. Long, Exec. VP & Chief Commercial Officer (Age 48)
  • Mr. Richard B. Evans Jr., Principal Accounting Officer, Sr. VP and Corp. Controller (Age 50)

Has R1 RCM been receiving favorable news coverage?

News coverage about RCM stock has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. R1 RCM earned a news impact score of 0.10 on Accern's scale. They also assigned media stories about the financial services provider an impact score of 45.66 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include TCP-ASC ACHI SERIES LLLP (59.80%) and JASPER RIDGE PARTNERS, L.P. (3.00%). Company insiders that own R1 RCM stock include Alex Mandl, John B Henneman III and Joseph Gerard Flanagan. View Institutional Ownership Trends for R1 RCM.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $8.81.

How big of a company is R1 RCM?

R1 RCM has a market capitalization of $955.11 million and generates $449.80 million in revenue each year. The financial services provider earns $-58,800,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. R1 RCM employs 9,965 workers across the globe.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The financial services provider can be reached via phone at 312-324-7820 or via email at [email protected]

MarketBeat Community Rating for R1 RCM (NASDAQ RCM)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  146 (Vote Underperform)
Total Votes:  265
MarketBeat's community ratings are surveys of what our community members think about R1 RCM and other stocks. Vote "Outperform" if you believe RCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.